Significant Options Trading on Wednesday: AMGN, SD, JNJ
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Source: NASDAQ.COM
SandRidge Energy Options Activity: SandRidge Energy Inc (SD) has seen a trading volume of 1,383 options contracts today, equating to about 138,300 underlying shares, which is 51.6% of its average daily trading volume over the past month.
High Volume Call Option for SandRidge: The $15 strike call option expiring on April 17, 2026, has particularly high activity with 764 contracts traded, representing approximately 76,400 underlying shares.
Johnson & Johnson Options Activity: Johnson & Johnson (JNJ) reported an options trading volume of 38,997 contracts today, which corresponds to around 3.9 million underlying shares, or 51% of its average daily trading volume over the past month.
High Volume Call Option for Johnson & Johnson: The $175 strike call option expiring on November 21, 2025, has seen significant trading with 3,133 contracts, representing about 313,300 underlying shares.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 342.220
Low
272.00
Averages
345.87
High
425.00
Current: 342.220
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Reaches $950 Billion Market Cap as GLP-1 Drug Leader
- Market Leadership: Eli Lilly has become the world's most valuable healthcare company with a market cap of approximately $950 billion, having seen its stock price soar 400% over the past five years, primarily driven by the popularity of its GLP-1 drugs, Mounjaro and Zepbound, indicating strong market demand and growth potential.
- New Drug Development Outlook: Amgen is developing a GLP-1 drug called MariTide, which offers a once-monthly injection treatment option that may appeal to patients preferring reduced injection frequency, thereby expanding its market share.
- Clinical Trial Results: In clinical trials, MariTide has demonstrated the ability to help patients lose up to 20% of their body weight over a 52-week period, comparable to existing GLP-1 treatments, highlighting its competitive edge in the weight loss market.
- Investment Value Analysis: Amgen's stock currently trades at a forward P/E ratio of 16, significantly lower than Eli Lilly's 32, indicating its relative undervaluation; if MariTide gains approval, the stock price could see substantial upside, making it an attractive investment opportunity.
Continue Reading
Eli Lilly vs Amgen: Stock Comparison Insights
- Valuation Discrepancy: Eli Lilly trades at over 30 times forward earnings with a market cap of approximately $950 billion, having seen a 400% stock price increase over the past five years, indicating strong performance in the GLP-1 drug market, yet its high valuation may pose risks for investors.
- Amgen's Potential: Amgen's GLP-1 drug MariTide is currently in phase 3 trials and may help patients lose up to 20% of their body weight over 52 weeks, with a forward P/E of just 16, suggesting a lower investment threshold and significant upside potential.
- Market Outlook: The GLP-1 drug market is projected to exceed $150 billion within the next decade, providing opportunities for companies like Eli Lilly and Amgen to capture substantial market share in this rapidly growing sector, attracting investor interest.
- Cautious Investment Advice: Despite MariTide's promising clinical results, analysts note that Amgen is not included in the current list of top investment stocks, urging investors to carefully assess potential risks and rewards before making investment decisions.
Continue Reading